Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis.

Clinical responses to placebo are higher in patients who continue an insufficient MTX background therapy. This suggests an inadvertently more consequent intake of background therapy during the trial. Background therapy should therefore be effectively aligned before enrollment into a clinical trial.